Ramon Alemany, Ph.D.

Chair

Ramon Alemany, Ph.D., is Head of the Immunotherapy and Virotherapy Group at the Translational Research Laboratory of the Institut Catala d’Oncologia (ICO) and Institut de Investigacio Biomedica de Bellvitage (IDIBELL). Dr. Alemany is a co-founder of VCN Biosciences and is an internationally recognized expert in oncolytic adenoviruses for cancer treatment. He has held various research positions across leading academic institutions, including MD Anderson Cancer Center, Baxter Healthcare Group and the University of Alabama at Birmingham. Dr. Alemany earned both his Ph.D., and B.S., from the University of Barcelona.